Insider Selling: Omeros (NASDAQ:OMER) Director Sells $276,750.00 in Stock

Omeros Corporation (NASDAQ:OMER) Director Thomas Cable sold 15,000 shares of Omeros stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $18.45, for a total value of $276,750.00. Following the transaction, the director directly owned 35,067 shares of the company’s stock, valued at $646,986.15. This trade represents a 29.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Omeros Price Performance

Omeros stock opened at $19.27 on Monday. The firm has a market capitalization of $1.39 billion, a PE ratio of 15.05 and a beta of 2.54. Omeros Corporation has a 52 week low of $3.94 and a 52 week high of $19.58. The firm’s 50-day simple moving average is $11.73 and its 200 day simple moving average is $11.76.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million. On average, research analysts expect that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Institutional Trading of Omeros

A number of hedge funds have recently added to or reduced their stakes in OMER. Compass Financial Management LLC purchased a new stake in Omeros in the 2nd quarter valued at about $312,000. Ancora Advisors LLC increased its stake in shares of Omeros by 46.7% during the 2nd quarter. Ancora Advisors LLC now owns 168,750 shares of the biopharmaceutical company’s stock valued at $1,605,000 after acquiring an additional 53,750 shares during the last quarter. Two Sigma Securities LLC purchased a new position in shares of Omeros during the 2nd quarter worth about $152,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Omeros by 9,655.4% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 53,362 shares of the biopharmaceutical company’s stock worth $507,000 after acquiring an additional 52,815 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of Omeros by 9.2% in the second quarter. Wellington Management Group LLP now owns 204,541 shares of the biopharmaceutical company’s stock worth $1,945,000 after acquiring an additional 17,241 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently weighed in on OMER shares. Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. HC Wainwright reiterated a “buy” rating on shares of Omeros in a report on Monday, July 27th. Finally, Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.00.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.